Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.
Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.
Aptevo Therapeutics (NASDAQ:APVO) announced its participation at the American Association for Cancer Research Virtual Annual Meeting, showcasing two key posters from April 10-15 and May 17-21, 2021. The posters cover preclinical updates on APVO603 and APVO442. APVO603 targets both 4-1BB and OX40, demonstrating significant anti-tumor response and safety in murine studies. APVO442, a bispecific candidate, shows strong efficacy and a favorable safety profile against PSMA+ tumors. Detailed abstracts will be available in the Virtual Poster Hall, allowing for presenter interactions.
Aptevo Therapeutics (NASDAQ:APVO) announced a significant advancement in its Phase 1/1b study of APVO436 for treating acute myeloid leukemia, with ongoing enrollment in cohort 10. The 2020 financial results showed a net loss of $17.75 million, an improvement from $40.45 million in 2019. Aptevo sold the RUXIENCE royalty payment stream for $35 million, with an additional $32.5 million possible based on sales milestones. The company maintains a strong balance sheet, allowing for continued clinical development. CEO Marvin White expressed optimism regarding the company's growth prospects.
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced on February 9, 2021, that it received a notice from Tang Capital Partners, LP (TCP) intending to nominate two candidates for election to the Board of Directors and to submit an advisory stockholder proposal for the upcoming 2021 Annual Meeting. The Company’s Board and management are committed to maximizing long-term stockholder value and will review the nominations and present their recommendations in a proxy statement. Stockholders are not required to take any action at this time.
Aptevo Therapeutics (NASDAQ:APVO) provided a significant update on its APVO436 Phase 1 clinical trial, revealing that patient dosing in cohorts 1-8 has been completed, with 36 patients enrolled. Encouragingly, no dose-limiting toxicities were noted in cohorts 5-8. Notably, two patients in cohort 6 achieved complete remission, highlighting potential efficacy. As the trial advances into cohort 9, Aptevo remains focused on improving patient outcomes. The company’s ADAPTIR platform continues to facilitate innovative bispecific antibody development, targeting cancers effectively.
Aptevo Therapeutics announced the launch of its new ADAPTIR-FLEX platform technology and introduced bispecific therapeutic candidate APVO442, targeting PSMA and CD3 for prostate cancer treatment. APVO442 aims to enhance binding strength to tumor antigens while maintaining a low affinity for T cells, potentially improving therapeutic outcomes. The company reported success in earlier clinical trials of its other candidate, APVO436, with two patients achieving complete remission. These advancements signify Aptevo's commitment to developing innovative immuno-oncology therapies.
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced an unsolicited non-binding offer from Tang Capital Partners, LP to acquire all outstanding shares of Aptevo not already owned for $50.00 per share. The Board of Directors will evaluate this proposal while fulfilling their fiduciary duties. They caution that no decisions have been made and that there are no guarantees of an accepted definitive offer. Shareholders do not need to act at this time. Aptevo is a biotechnology company focused on developing immuno-oncology therapeutics using its ADAPTIR™ technology.
Aptevo Therapeutics and Alligator Bioscience announced a partnership to advance ALG.APV-527, a bispecific antibody targeting solid tumors expressing 5T4. The drug is entering Phase 1 clinical development, with plans to file for Clinical Trial Authorization in early 2021.
Recent data from another candidate, APVO436, showing complete remission in patients enhances confidence in ALG.APV-527's potential. The collaboration aims to explore licensing opportunities as clinical development progresses.
Aptevo Therapeutics reported a net loss of $6.8 million for Q3 2020, slightly improved from $6.9 million in Q3 2019. The company generated $1.5 million in royalties from Pfizer's RUXIENCE, resulting in a 209% increase from the previous quarter. R&D expenses decreased to $4.5 million from $7.6 million in 2019, primarily due to COVID-19 impacts. Aptevo's cash reserves stood at $27.5 million, extending its runway into 2022. The Phase 1/1b trial for APVO436 continues, with promising preliminary results showing complete remission in two patients.
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its participation in the 35th Virtual Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 9-14, 2020. The company will present two posters showcasing advances in its therapies: APVO603, which enhances anti-tumor responses, and ALG.APV-527, which shows a favorable safety profile. Live Q&A sessions for both presentations are scheduled for November 11 and 13. These developments highlight Aptevo's commitment to innovative cancer treatment using its proprietary ADAPTIR bispecific technology.
Aptevo Therapeutics has announced a significant update on its APVO436 Phase 1 trial for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
On November 6, the company reported a second complete remission in Cohort 6, bringing the total to two out of nine patients in this group. Data showed one patient with stable disease, while six experienced disease progression. Enrollment in Cohort 8 has commenced, and preliminary pharmacokinetic modeling indicates potential for clinical activity in upcoming cohorts.
Aptevo's proprietary ADAPTIR platform underpins this promising therapy, positioning it as a cost-effective alternative to traditional CAR-T therapies.